Science Pool

Evotec invests into Oxford Cell Therapy Company "OxVax"

Evotec SE announced today that the Company has invested into OxVax, a new immuno-oncology company based on research from Oxford University, which enables the development of the next generation of cancer vaccines with the potential to overcome the limitations of the current approaches.
Read More

Generated by Feedzy